The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): China continuation of TOURMALINE-MM1.
 
Jian Hou
No Relationships to Disclose
 
Jie Jin
No Relationships to Disclose
 
Yan Xu
No Relationships to Disclose
 
Depei Wu
No Relationships to Disclose
 
Xiaoyan Ke
No Relationships to Disclose
 
Zhou Daobin
No Relationships to Disclose
 
Jin Lou
No Relationships to Disclose
 
Xin Du
No Relationships to Disclose
 
Xiequn Chen
No Relationships to Disclose
 
Junmin Li
No Relationships to Disclose
 
Jing Liu
No Relationships to Disclose
 
Bingxia Wang
Employment - Millennium
Stock and Other Ownership Interests - Takeda
 
Xiaoquan Zhang
Employment - Millennium
 
Hui Wang
Employment - Millennium
Stock and Other Ownership Interests - Takeda
 
Helgi Van De Velde
Employment - Millennium
Stock and Other Ownership Interests - Takeda
 
Paul G. Richardson
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Genmab; Johnson & Johnson; Millennium; Novartis; Oncopeptides
Research Funding - Celgene; Millennium
 
Philippe Moreau
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda